Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hey there. This is Matthew Herper. It was a little chillier in San Francisco this morning, and you can feel many JPM attendees dragging a bit from trying to pack a month into a day. It doesn’t help that, a day after J&J, Eli Lilly, and GSK all announced deals that gave some observers hope of a resurgence in M&A, Lilly, the mightiest drug company in the land — or at least the biggest by market cap — announced an earnings miss. But we’re all still here, and we have an exclusive podcast interview with Lilly CEO Dave Ricks at the bottom of this newsletter. Stay tuned.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
